BioChat #19: The Magic of Antibody Engineering
Manage episode 397333551 series 3464173
The Chief Scientific Officer at Yurogen, Hao Cheng, PhD, joins BioChat to discuss the necessity of antibody engineering to produce safer and more effective research tools and therapeutics. Dr. Cheng gives insight into the many considerations and processes involved in taking an antibody from its raw form to an optimized reagent with altered binding dynamics and/or improved deliverability.
We also invite you to listen to Dr. Wu's discussion of the SMab platform here.
Yurogen is a subsidiary of ABclonal Technology, you can visit our website at Yurogen.com. To view the presentation of our antibody engineering platform, please fill out our form here.
Please feel free to visit us at www.abclonal.com, read our blog posts here, including an introduction to what we're hoping to accomplish with BioChat, and check out our Doctor Beaker page for fun activities! You can also find all the ways to subscribe to our podcast via our BioChat page, which includes Apple Podcasts and Spotify.
28 episode